AGTR1 angiotensin II receptor type 1
ENSG00000144891 · protein coding · Open Targets profile
Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney (PubMed:15611106, PubMed:1567413, PubMed:25913193, PubMed:26420482, PubMed:30639100, PubMed:32079768, PubMed:8987975). The activated receptor in turn couples to G-alpha proteins G(q) (GNAQ, GNA11, GNA14 or GNA15) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C (PubMed:15611106). {ECO:0000269|PubMed:15611106, ECO:0000269|PubMed:1567413, ECO:0000269|PubMed:25913193, ECO:0000269|PubMed:26420482, ECO:0000269|PubMed:30639100, ECO:0000269|PubMed:32079768, ECO:0000269|PubMed:8987975}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Database Ubiquitination, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.8229100108146667 (upper bound 1.249899983406067). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 246 registry trials, updated in the last three years, of the most advanced drugs against AGTR1 (saralasin, azilsartan kamedoxomil, angiotensin ii, tasosartan, eprosartan, sparsentan, fimasartan, losartan, azilsartan, candesartan cilexetil, olmesartan medoxomil, candesartan), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Radko KomersTravere Therapeutics, Inc. · 5 of 5 trials Phase 2+
- David ZhuMichigan State University · 2 of 2 trials Phase 2+
- Joao P TeixeiraUniversity of New Mexico · 2 of 2 trials Phase 2+
- Johnny HuardSteadman Philippon Research Institute · 2 of 2 trials Phase 2+
- Joshua RozellNYU Langone Health · 2 of 2 trials Phase 2+
- Nancy K SweitzerUniversity of Arizona · 2 of 2 trials Phase 2+
- Nathan D NielsenUniversity of New Mexico · 2 of 2 trials Phase 2+
- Wanpen VongpatanasinUniversity of Texas Southwestern Medical Center · 2 of 2 trials Phase 2+
- Mark D HuffmanNorthwestern University · 1 of 2 trials Phase 2+
- Alberto J Zamora Muciño-ArroyoInvestigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-AGS) · 1 of 1 trials Phase 2+
- Alberto ZanchettiIstituto Auxologico Italiano. Milan. Italy · 1 of 1 trials Phase 2+
- Alejandro BalestracciHospital General de Niños Pedro de Elizalde · 1 of 1 trials Phase 2+
- Alexander EgbeMayo Clinic · 1 of 1 trials Phase 2+
- Alexander H FlanneryUniversity of Kentucky · 1 of 1 trials Phase 2+
- Alexander ZarbockUniversity Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy · 1 of 1 trials Phase 2+
Registry trials of saralasin, azilsartan kamedoxomil, angiotensin ii, tasosartan, eprosartan, sparsentan, fimasartan, losartan, azilsartan, candesartan cilexetil, olmesartan medoxomil, candesartan updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 187 of 212 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 34 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
117 trials of drugs against AGTR1 were stopped early; 7 give no reason
Terminated, withdrawn and suspended interventional trials of saralasin, azilsartan kamedoxomil, angiotensin ii, tasosartan, eprosartan, sparsentan, fimasartan, losartan, azilsartan, candesartan cilexetil, olmesartan medoxomil, candesartan, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 117.
- withdrawn · 2026-10-26 · Eurofarma Laboratorios S.A. · matched by the registry's drug synonyms“Strategic change in development priorities.”
- terminated · 2026-09-24 · Milton S. Hershey Medical Center · matched by the registry's drug synonyms“Funding terminated”
- terminated · 2026-04-13 · Northwestern University · Angiotensin II“Enrollment Challenges”
- terminated · 2026-01-13 · University of California, San Francisco · Anti-hypertensive agent: Losartan“Funding limitations.”
- withdrawn · 2025-12-08 · EMS · Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg, Olmesartan medoxomil 20mg + Chlortalidone 25mg“Decided by Sponsor”
- withdrawn · 2025-12-08 · EMS · Olmesartan medoxomil 40mg + chlorthalidone 12,5mg, Olmesartan medoxomil 40mg + chlorthalidone 25mg“Decided by Sponsor”
- terminated · 2025-06-04 · University of Arizona · matched by the registry's drug synonyms“Funding ended”
- suspended · 2025-06-04 · University of Arizona · matched by the registry's drug synonyms“Study Suspended. Slow enrollment.”
- withdrawn · 2024-12-27 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Losartan“No patients enrolled”
- withdrawn · 2024-09-23 · NYU Langone Health · Losartan“Study team unable to identify method for approval of the medication as standard of care and compounded.”
- terminated · 2024-08-15 · Organon and Co · MK0954, losartan potassium / Duration of Treatment - 12 weeksNo reason given
- terminated · 2024-06-24 · Assistance Publique Hopitaux De Marseille · Losartan 50 mg and Spironolactone 25 mg pillules oral use“due to an Urgent Security Measure”
- terminated · 2024-06-18 · Organon and Co · hydrochlorothiazide (+) losartan potassium, losartan potassium, Placebo for Losartan, Placebo for Losartan/HCTZ“Achieving site readiness and enrolling the trial within a reasonable time”
- terminated · 2024-06-10 · Amy Arnold · matched by the registry's drug synonyms“Funding terminated”
- terminated · 2024-05-03 · Milton S. Hershey Medical Center · matched by the registry's drug synonyms“Study funding ended prior to completion.”
- terminated · 2024-05-02 · James J. Irrgang · Losartan“The study was terminated due to difficulty identifying eligible participants and the expiration of funding.”
- terminated · 2024-04-03 · University of Alabama at Birmingham · Losartan“Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.”
- withdrawn · 2024-03-15 · University of New Mexico · Angiotensin II“Funding and protocol changes. Replaced with new pilot trial.”
- withdrawn · 2024-03-06 · University of California, Los Angeles · Angiotensin II“Funding issues; the study was never started”
- terminated · 2024-03-04 · OHSU Knight Cancer Institute · Losartan“Low accrual”
- terminated · 2024-02-20 · Istituto Auxologico Italiano · Losartan Tablets“Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.”
- terminated · 2024-01-09 · Vanderbilt University · matched by the registry's drug synonyms“We were not able to enroll adequate number of participants that met the inclusion/exclusion criteria, and we run out of funding.”
- terminated · 2024-01-03 · Alere San Diego · matched by the registry's drug synonyms“Sponsor's discretion to terminate study prematurely for further evaluation.”
- withdrawn · 2023-12-01 · NYU Langone Health · Losartan“Study was not initiated, no participants enrolled.”
- terminated · 2023-12-01 · US Biotest, Inc. · matched by the registry's drug synonyms“Unable to enroll in timely manner due to nature of COVID”
Paediatric incentives and obligations for AGTR1's drugs
For saralasin, azilsartan kamedoxomil, angiotensin ii, tasosartan, eprosartan, sparsentan, fimasartan, losartan, azilsartan, candesartan cilexetil, olmesartan medoxomil, candesartan: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · AGTR1 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000226166 (sparsentan, Treatment of primary IgA nephropathy): PM: decision on the application for modification of an agreed PIP, 16 May 2025; EMEA-003466-PIP01-23 (amlodipine;atorvastatin;Candesartan, Prevention of cardiovascular events): W: decision granting a waiver in all age groups for all conditions or indications, 1 Dec 2023; EMEA-001912-PIP02-16-M03 (angiotensin II (LJPC-501), Treatment of hypotension associated with distributive or vasodilatory shock): PM: decision on the application for modification of an agreed PIP, 25 Oct 2023; EMEA-001984-PIP02-20-M01 (sparsentan, Treatment of focal segmental glomerulosclerosis): PM: decision on the application for modification of an agreed PIP, 21 Apr 2023; +28 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/22/2622 positive 21 Jun 2022: Treatment of osteogenesis imperfecta; EU/3/19/2142 positive 26 Feb 2019: Treatment of epidermolysis bullosa; EU/3/20/2345 positive 19 Oct 2020: Treatment of primary IgA nephropathyRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Giapreza: authorised since 23 Aug 2019; Filspari: authorised since 19 Apr 2024, orphan medicineRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of saralasin, azilsartan kamedoxomil, angiotensin ii, tasosartan, eprosartan, sparsentan, fimasartan, losartan, azilsartan, candesartan cilexetil, olmesartan medoxomil, candesartanRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 84 interventional studies of saralasin, azilsartan kamedoxomil, angiotensin ii, tasosartan, eprosartan, sparsentan, fimasartan, losartan, azilsartan, candesartan cilexetil, olmesartan medoxomil, candesartan include patients under 18; 7 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 23 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.